Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2944210 | 0.84 | BACE1 (0.32) | BACE1IDO1 | |
| SCHEMBL17094641 | 0.82 | BACE1 (0.33) | BACE1IDO1 | |
| SCHEMBL12002597 | 0.77 | IDO1 (0.57) | BACE1IDO1 | |
| SCHEMBL20386687 | 0.75 | BACE1 (0.32) | BACE1 | |
| SCHEMBL5744241 | 0.74 | BACE1 (0.33) | BACE1 | |
| SCHEMBL3366390 | 0.74 | IDO1 (0.38) | BACE1IDO1 | |
| SCHEMBL20742459 | 0.73 | BACE1 (0.33) | BACE1 | |
| SCHEMBL23604474 | 0.72 | BACE1 (0.41) | BACE1 | |
| SCHEMBL16062052 | 0.72 | BACE1 (0.34) | BACE1 | |
| SCHEMBL6155969 | 0.71 | IDO1 (0.38) | BACE1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12398111-B2 | Triazine compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2025-08-26 | — | — | US | disclosed |
| US-20230011968-A1 | TRIAZINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2023-01-12 | — | — | US | disclosed |
| US-20230011968-A1 | TRIAZINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2023-01-12 | — | — | US | disclosed |
| US-20200087266-A1 | TRIAZINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2020-03-19 | — | — | US | disclosed |
| EP-3456713-A1 | PROCESS FOR THE PREPARATION OF TRIAZINE DERIVATIVES | Japan Tobacco Inc. (JP) | 2019-03-20 | — | — | EP | disclosed |
| EP-3109240-B1 | TRIAZINE COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | JAPAN TOBACCO INC (JP) | 2018-10-24 | — | — | EP | disclosed |
| EP-3109240-A1 | TRIAZINE COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | Japan Tobacco, Inc. (JP) | 2016-12-28 | — | — | EP | disclosed |
| US-20150266834-A1 | TRIAZINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2015-09-24 | — | — | US | disclosed |
| US-20150266834-A1 | TRIAZINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2015-09-24 | — | — | US | disclosed |
| US-20150266834-A1 | TRIAZINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2015-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266834-A1 | TRIAZINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | PTGIS, PTGS1, PTGES | BACE1 348/4885IDO1 393/4885 |
| US-20200087266-A1 | TRIAZINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | PTGIS, PTGS1, PTGES | BACE1 348/4885IDO1 393/4885 |
| US-12398111-B2 | Triazine compounds and pharmaceutical use thereof | PTGIS, PTGS1, PTGES | BACE1 348/4885IDO1 393/4885 |
| US-20230011968-A1 | TRIAZINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | PTGIS, PTGS1, PTGES | BACE1 348/4885IDO1 393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.